Wholesale Raw Material Grade 99% High Purity Linagliptin Powder CAS 668270-12-0
Contact Supplier
Still deciding? Get samples of $ !
Request Sample
Product Highlights
- High Purity Grade: 99% purity Linagliptin powder with CAS 668270-12-0.
- Free Samples Available: Free samples provided, buyer pays freight.
- Fast Delivery: Standard delivery within 15 days.
- Flexible MOQ: Standard MOQ 1kg, 100g accepted with sample charge.
- Third-Party Inspection: SGS inspection available before shipping.
- Quality Guarantee: Free replacement or refund for quality issues caused by us.
- Multiple Payment Options: Accepts T/T, PayPal, Western Union, LC, and D/P.
- Experienced Supplier: Over 20 years in chemical raw materials with GMP/ISO certified bases.
Product Attributes
- Customization
- Available
- CAS No.
- 668270-12-0
- Formula
- C25h28n8o2
- Model NO.
- CAS 668270-12-0
- Type
- Synthesis Material Intermediates
- Appearance
- Liquid
- Quality
- Industrial
- Colour
- White
- Model No.
- 668270-12-0
- Sample
- Available
- Delivery
- 15 Days
- Transport Package
- 1kg Per Foil Bag, 10 Bags Per Carton. 25 Kg Per Dr
- Specification
- 1kg Per Foil Bag, 10 Bags Per Carton. 25 Kg Per Dr
- Trademark
- HIGHWIN
- Origin
- China
- Production Capacity
- 30000ton/Year
Product Images of Wholesale Raw Material Grade 99% High Purity Linagliptin Powder CAS 668270-12-0
Find Similar Products
Product Description

| Product Name | Wholesale 99% Purity Raw Material Linagliptin Powder CAS 668270-12-0 Linagliptin |
| Appearance | Powder |
| cas | 668270-12-0 |
| Assay | 99% |
| Keywords | Linagliptin;Raw Powder Linagliptin;Purity Linagliptin Powder |
| Shelf Life | 24 months when properly stored |
| Storage | Keep in a cool, dry, dark location |
What is Linagliptin ?
Linagliptin (trade names Tradjenta and Trajetna) is an inhibitor of dipeptidyl peptidase-4 (DPP-4) that was approved by the U.S. FDA in May 2011 for the treatment of Type 2 diabetes along with diet and exercise. Linagliptin (BI-1356) has been described as a potent highly selective, slow-off rate and long acting inhibitor of DPP-4.
Linagliptin arose from optimization efforts of xanthine-based DPP-4 inhibitors with the initial lead identified from an HTS campaign. After optimizing the activity of the initial micromolar lead, two issues that needed to be addressed were activity for hERG and muscarinic receptor M1.